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Abstract 
         Objective: the aim of this study was to access the potential involvement of MIF in SLE, 
its relationship with corticosteroid dose, also, to measure serum and urinary MIF levels in SLE 
as well as detecting renal MIF expression in
 SLE GN.  
         Methods:  Serum  and  urine  MIF  concentrations  were  measured
  by  enzyme-linked 
immunosorbent  assay  in  20
  SLE  female  patients  with  lupus  nephritis  ,  World  Health 
Organization class
 II, III, IV, with mean age of 35.1510.42 years and in 10 normal healthy, age 
matched,  female  volunteers.  All  patients  were  subjected  to  detailed  clinical  assessment  and 
laboratory  investigations.  Serum  and  urinary  MIF  concentrations  were  measured  by  ELISA 
technique. Renal MIF expression was assessed by immunostaining of
 biopsy tissue. Univariate 
and multivariate regression analysis were used to examine the associations between serum and 
urine  MIF  concentrations,  renal  MIF  expression,  disease-related  indices  of  SLE  and 
corticosteroid use.  
         Results: A statistically significant 2.98-fold-increase was detected in mean urinary MIF      
(U MIF) levels in SLE patients compared to controls. While, mean Serum MIF (S MIF) showed 
no  significant  difference  between  cases  &  control.  Both  S  &  U  MIF  concentrations  were 
positively correlated with SLICC/ACR DI but not with SLEIDAI. Corticosteroid doses showed 
a highly positive correlation with S MIF, serum creatinine & SLICC/ACR DI. Also a positive 
correlation was found between the different histopathologic grades of renal affection & the U 
MIF.  Immunohistochemistry  staining  of  all  normal  kidney  specimens  showed  that  MIF  is 
constitutively  weakly  expressed  by  some  glomerular  &  parietal  epithelial  cells  &  by  most 
tubular epithelial cells. In contrast, there was a significant increase in glomerular & tubular MIF 
protein staining in SLE nephropathy. This increased MIF expression correlated positively with 
both S MIF and U MIF, SLICC/ACR DI & the daily steroid dose   
         Conclusion: This study shows that serum MIF is over-expressed in SLE patients and that 
the urine
 MIF concentration is significantly increased in SLE World Health Organization class
 
IV patients and correlates with the degree of renal injury. Thus,
 urine MIF levels reflect MIF 
expression within the kidney. 
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Introduction 
         
         Originally  described  in  1966, 
macrophage  migration  inhibitory
  factor 
(MIF) was initially identified as a 12.5-kD 
protein secreted by activated T lymphocytes 
capable  of  inhibiting  random  migration  of 
macrophages,  concentrating  macrophages 
at  inflammatory  loci,  and  enhancing  their 
ability  to  kill  intracellular  parasites  and 
tumour  cells  (David,1966).  Recent  data 
indicate  that  other  types  of  cells,  such  as 
macrophages,  endothelial  cells,  and 
fibroblasts, can  produce MIF  (Steinhoff  et 
al.,  1999),  and  many  other  functions  have 
been attributed to this molecule, such as the 
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regulation  of  cell  growth,  including 
tumourigenesis,  T  cell  activation,  and 
angiogenesis  (Lolis,  2001).  MIF  is 
constitutively  expressed  by  B  cells,  and 
antagonism  of  MIF  inhibits  B  cell 
proliferation  (Chesney  et  al.,  1999).  It  is 
also  produced  by  T  cells  stimulated  by 
recall  antigens,  mitogens,  and  anti-CD3 
antibodies, and antagonism of MIF prevents 
T cell activation by these factors (Bacher  et 
al.,  1996).  Furthermore,  recent  reports 
suggest  that  MIF  has  a  critical  role  in 
inflammatory and immune responses (Metz 
and Bucala, 1997). In particular, MIF has 
been shown to induce the synthesis of pro-
inflammatory  cytokines,  including  tumour 
necrosis  factor-  (TNF-),  interleukin 
(IL)1  and  IL8  in  immunocompetent  cells. 
Moreover,  it  has  also  been  verified  that 
MIF acts as a powerful stimulator for nitric 
oxide production (Liew, 1994).  
         MIF  is  the  only  molecule  described 
that  can  override  the  anti-inflammatory 
action  of  glucocorticoids  (Calandra  et  al., 
2000). Moreover, in  animal models and  in 
vitro, MIF has the unique ability to exert an 
antagonistic  effect  on  corticosteroid 
suppression  of  immune  inflammation 
(Santos  et  al.,  2001).  This  is  in  contra-
diction  with  the  role  of  MIF  as  a  pro-
inflammatory  cytokine,  but  it  supports  the 
concept  that  physiologic  levels  of 
glucocorticoids  regulate  the  immune 
inflammatory response (Amoli et al., 2002). 
MIF also acts in a dose dependent manner 
in  regulating  the  inhibitory  effects  of 
glucocorticoids  in  the  immune  system 
(Donnelly  and  Bucala,  1997).  MIF  is 
inhibited  by  pharmacological  concentra-
tions  of  glucocorticoids.  However,  at  low 
concentrations  these  drugs  increase  the 
synthesis of MIF (Leech et al., 2000). The 
hypothesis  that  MIF  operates  as  a 
physiological  counter-regulator  of  cortico-
steroids  (Fingerle-Rowson  et  al.,  2003)  
suggest that therapeutic antagonism of MIF 
may  have  specific  steroid-sparing  benefits, 
by  increasing  the  immunosuppressive  and 
anti-inflammatory  properties  of  endoge-
nously  released  glucocorticoids,  thus 
reducing the requirement for steroid therapy 
in  a  variety  of  autoimmune  and  inflamm-
atory conditions (Bucala, 1998). 
         As  mentioned  in  several  previous 
reports, an essential role for MIF
 has been 
established  in  the  tuberculin  delayed-type 
hypersensitivity
 reaction  (Bernhagen  et  al., 
1996),  in  several  inflammatory  skin 
diseases (Steinhoff et al., 1999), in wound 
healing  process  (Abe  et  al.,  2000),  in 
immune-mediated  diseases  of  the  central 
nervous system (Niino et al., 2000) and in 
inflammatory bowel disease (De Jong et al., 
2001).  
         MIF potentiates lethal
 endotoxemia in 
mice  and  can  overcome  glucocorticoid-
mediated
 suppression of lethal endotoxemia 
(Calandra  et  al.,  2000).  A  pathologic
 role 
for MIF has also been established in expe-
rimental models
 of arthritis (Mikulowska et 
al., 1997), where MIF showed a pivotal role 
in  the  pathogenesis  of  rheumatoid  arthritis 
(RA)  (Leech  et  al.,  1998  and  2003)  and 
glomerulonephritis  (GN)  (Lan  et  al.,  1997 
a) which has led to increasing acceptance of 
MIF  as  a  key  cytokine  in  chronic  inflam-
matory  diseases.  The  adminstration  of 
specific  anti-MIF  monoclonal  antibodies 
decrease arthritis disease expression (Leech 
et al., 2000) and inhibit the severity as well 
as  frequency  of  disease  (Sampey  et  al., 
2001). 
The  dysregulation  of  MIF  has 
recently  been  described  in  several  inflam-
matory  diseases  (Meazza  et  al.,  2002). 
Leech  et  al.  (1999)  demonstrated  the  high 
expression  of  MIF  in  inflamed  synovial 
tissue from RA patients, with a unique up 
and down regulation, respect-ively, induced 
by  low  and  high  glucocorticoid  concen-
trations.  Morand  et  al.  (2002)  found  a 
strong  correlation  between  the  synovial 
MIF  and  disease  activity  which  corrob-
orates existing  evidence  of the  role  of  this 
cytokine  in  RA.  These  findings  were 
recently  confirmed  by  Onodera  et  al  . 
(2004)  who  explained  the  migration  of 
inflammatory  cells  into  the  synovium  of 
rheumatoid joints to be due to induction of 
IL8  and  IL1-beta  mRNA  which  are  up 
regulated  by  MIF.  Meazza  et  al.  (2002) 
reported that MIF is a relevant cytokine in 
the  pathogenesis  of  juvenile  idiopathic 
arthritis  (JIA),  particularly  in  systemic-
onset JIA. Also, in a recent study done by 
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haplotype  of  MIF  was  found  to  be  linked 
and  associated  with  JIA.  Sampey  et  al. 
(2001)  showed  that  MIF  exerts  an  up 
regulation  of  fibroblast-like  synoviocyte 
phospholipase  A2  and  cyclooxygenase  2. 
Selvi  et  al.  (2003)  found  a  significantly 
higher  serum  concentration  of  MIF  in 
patients  with  diffuse  systemic  sclerosis. 
Also, they found a significantly higher MIF 
level in the fibroblast cultures. Of particular 
interest in SLE is the observation that MIF 
is the only proinflammatory cytokine that is 
induced  rather  than  suppressed  by 
corticosteroids  (Leech  et  al.,  1999).  This 
was confirmed by Foote et al. (2004) who 
found that serum MIF was overexpressed in 
SLE patients. 
         SLE is a chronic multisystem autoim-
mune  disease  with  an  unknown  etiology, 
characterized  by  abnormalities  of  immune-
inflammatory  system  function  including 
altered  B  and  T  cell  function,  and  by 
inflammation of organs including joints and 
kidneys (Lipsky, 2001). Corticosteroids are 
a mainstay of the treatment of SLE, despite 
their widely known side effects. 
         In  the  kidney,  MIF  is  weakly
 
expressed  by  some  glomerular  epithelial 
cells  and  by  approximately
  half  of  the 
cortical  tubules  (Lan  et  al.,  1998).  Renal 
MIF mRNA and protein
 expression is upre-
gulated  in  different  types  of  experimental
 
kidney  disease,  including  crescentic  anti–
glomerular basement
 membrane GN (Tesch 
et al., 1998). In each of these disease mod-
els,  up-regulation  of  MIF  expression  is 
closely  associated  with  macrophage  accu-
mulation  and  tissue  damage.  Tang  et  al. 
(1994) reported that  induction of the  early 
renal injury in this disease model is largely 
attributed  to  the  early  and  transient 
neutrophil  influx  after  the  deposition  of 
antibody  and  complement  on  the  glome-
rular  basement  membrane.  In  contrast,  the 
subsequent  progression  of  renal  injury  is 
mediated  by  macrophages  and  T  cells, 
which  supports  the  concept  that  MIF  is  a 
key  regulator  of  immune  disease  mediated 
by  macrophages  and  T  cells  (Lan  et  al., 
1997b).  Administration
  of  a  neutralizing 
anti-MIF  antibody  inhibited  macrophage 
and
  T  cell  accumulation  and  histologic 
damage, reduced proteinuria,
 and prevented 
renal  dysfunction  in  rat  crescentic  anti–
glomerular
  basement  membrane  disease 
(Lan et al., 1997 b). Furthermore, adminis-
tration
 of the anti-MIF antibody was shown 
to partially reverse the
 progressive phase of 
established crescentic disease in rats (Yang 
et al., 1998).
  
         Analysis  of  renal  MIF  expression  in 
human  biopsy  tissue  revealed
  that  renal 
MIF  expression  is  upregulated  in  prolifer-
ative  forms
 of  GN.  Renal  MIF  expression 
significantly  correlates  with
  renal 
dysfunction,  histologic  damage,  and 
leukocytic  infiltration
  (Lan  et  al.,  2000). 
Taken  together  with  data  from  functional 
blocking  studies
  in  the  rat.  These  data 
suggest that MIF plays an important role
 in 
the pathogenesis of human proliferative GN 
and  could  be  an  attractive  target  in  the 
treatment of progressive human GN.  
Despite  the  accumulation  of 
evidence  for  a  key  role  for  MIF  in 
autoimmune-inflammatory  diseases,  MIF 
has  not  been  extensively  investigated  in 
SLE. Based on the hypothesis that urinary 
MIF
 excretion may reflect the level of MIF 
production  within  the
  kidney,  which  may 
furthermore  reflect  the  degree  of  renal 
injury, the aim of this study was to access 
the  potential  involvement  of  MIF  in  SLE, 
its  relationship  with  corticosteroid  dose, 
also,  to  measure  serum  and  urinary  MIF 
levels  in  SLE  as  well  as  detecting  renal 
MIF expression in
 SLE GN.  
 
Material and Methods 
 
Patients 
 
         Twenty  female  SLE  patients  who 
fulfilled  the  American  criteria  for 
classification of SLE (Tan et al., 1982) with 
lupus nephritis WHO class II, III, IV were 
recruited  from  the  outpatient  clinic  of 
Rheumatology & Rehabilitation and nephr-
ology departments at Ain Shams University 
Hospital  and  were  enrolled  in  this  study. 
Their  mean  age  was  35.1510.42  years 
(range18-53 years). 
         Ten  age-matched  apparently  healthy 
female volunteers, with no history of acute 
or  chronic  inflammatory  disease,  were 
enrolled  from  the  department  personnel  as Nahla Khattab et al     
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controls.  Their  mean  age  was  33.211.43 
years (range 19-50 years).  
   
All patients  and controls  were  subjected 
to: 
Clinical evaluation 
         All  patients  had  a  detailed  clinical 
assessment  for  involvement  of  the  internal 
organs and were evaluated for the presence 
of  gastrointestinal,  pulmonary,  cardiac, 
renal, or musculoskeletal affection.  
         Disease  damage  was  measured  using 
Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology 
Damage Index (SLICC/ACR DI) (Gladman 
et al., 1996) and disease activity was asses-
sed  using  the  Systemic  Lupus  Erythem-
atosus  Disease  Activity  Index  (SLEDAI) 
(Bombardier  et  al.,  1992).  Patients  were 
classified as inactive if their SLEDAI score 
was less than 5, and active if their SLEDAI 
score was more than 10.  
         Each  patient  was  assessed  for 
concomitant  medication  and  corticosteroid 
dose  was  recorded  as  the  daily  dose  of 
Prednisolone  (mg/day)  at  the  time  of  the 
study.  
 Laboratory assessment 
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Serum Samples  
         All  collected  blood  samples  were 
limited  between  9  am  and  12  pm.  Blood 
was  withdrawn  by  venipuncture  in  plain 
tubes and left at room temperature
 for 1 hr 
rto clot before being stored at 4°C for up to 
4  hr.
  The  blood  then  was  centrifuged  at 
1500 x g for 10 min. The serum
 was formed 
into aliquots and stored at -80°C. Only one 
freeze-thaw cycle was allowed. 
Urine Samples 
         Sterile midstream urine samples were 
collected from patients
 and then were stored 
at 4°C for a maximum of 12 hr before
 pro-
cessing.  A  1-ml  aliquot  was  analyzed  for 
urine  creatinine  and  protienuria.
 The  urine 
was centrifuged at 1500 x g for 10 min to 
separate
  debris  and  a  protease  inhibitor 
cocktail  (Sigma,  Castle  Hill,
  New  South 
Wales,Australia) was added; then urine was 
formed
 into aliquots and stored at -80°C.  
 
Serum  and  urine  MIF  Enzyme-Linked 
Immunosorbent Assay
  
         Serum  and  urine  MIF  concentrations 
were  quantitated  by  enzyme-linked
 
immunosorbent assay (ELISA) according to 
the  manufacturer’s
  instructions  (R&D 
Systems,  Minneapolis,  MN).  In  brief, 
ELISA plates were coated overnight with 2 
µg/ml (100µl/well)  mouse
 anti-human  MIF 
capture antibody and incubated overnight at 
room  temperature.  Wells  were  washed  3 
times with washing solution (10 mM PBS; 
pH 7.4, 0.05% (wt/vol)
 Tween-20), blocked 
by 300µl of blocking solution (10mM PBS; 
pH7.4,  1%  (wt/vol)  bovine
 serum  albumin 
(BSA),  5%  (wt/vol)  sucrose,  and  0.05% 
NaN3  in  PBS)  for  2  hr.  Test  samples
 
(human  serum,  human  urine,  or 
recombinant MIF standards) diluted
 in Tris 
buffered  saline-BSA  (0.1%  BSA,  0.05% 
Tween-20,  20  mM  Tris-HCl,  150  mM 
NaCl,
  pH  7.3),  were  added  in  triplicate 
(100µl/well)  and  then  incubated  at  room
 
temperature  for  2  hr.  After  washing  with 
PBST, bound  MIF was
 detected by  a  2-hr 
incubation with 200 ng/ml biotinylated anti-
human
 MIF antibody diluted in 0.1% BSA, 
0.05% Tween-20 in 20 mM  Tris-HCl,
 and 
150  mM  NaCl,  pH  7.3.  After  washing, 
samples  were  incubated
  with  1.25  ng/ml 
peroxidase-conjugated streptavidin  (Zymed, 
South
  San  Francisco,  CA)  for  30  min, 
washed in PBST, and then incubated
 for 30 
min with 100 µl/well ready-to-use 3,3',5,5;-
tetramethylbenzidine
  (Zymed)  and  the 
colorimetric  reaction  stopped  after  20 
minutes  by  the  addition
 of  0.5  M  H2SO4. 
The  adsorption  was  measured  at  450/570 
nm  with
  a  microplate  reader.  MIF 
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serum  or  pg  MIF/µmol  for  urine.  The 
sensitivity limit was 18 pg/ml.  
         MIF  is  stable  in  human  urine;  the 
ELISA measurements are constant
 for up to 
24  hr  when  stored  at  4°C  or  room 
temperature.  The
  MIF  ELISA  assay  is 
highly reproducible, and when we analyzed
 
samples  (in  triplicate)  up  to  12  times,  the 
SD was 6.6% of the
 mean value.
  
   
Renal biopsies and histopathology 
         Renal  biopsies  were  taken  from  7 
female  SLE  patients,  World  Health 
Organization  class  II,  III  and  IV.  In 
addition,  five  normal  human  kidney 
specimens  were  analyzed
 (from  unaffected 
areas  of  nephrectomy  for  renal  cell 
carcinoma).  
Sections  (4  µm)  of  formalin-fixed, 
paraffin-embedded  biopsy
  tissue  were 
stained  with  hematoxylin  and  eosin.  The 
percentage
 of  glomeruli  exhibiting  crescent 
formation  was  scored  in  10-30  glomerular 
cross sections (gcs) per biopsy. Glomerular
 
hypercellularity was assessed as follows: 0 
= normal (less than
 60 cells/gcs); 1 = mild 
(60-90  cells/gcs);  2  =  moderate  (90-120 
cells/gcs);  and  3  =  severe  (more  than  120 
cells/gcs).
  
 
Antibodies 
   Mouse  monoclonal  antibodies 
(MoAb)  used  for  immunostaining  were
 as 
follows: IIID9, mouse MoAb raised against 
recombinant  mouse
  MIF  that  cross-reacts 
with  human  MIF;  UCHL1,  mouse  anti-
CD45RO,
  which  recognizes  mature, 
activated T cells and a subset of resting
 T 
cells (Smith et al.,1986); and KP1,  mouse 
anti-CD68,  which  labels  most  monocytes
 
and  macrophages  (Pulford  et  al.,  1989). 
Peroxidase  and  alkaline  phosphatase–
conjugated
  goat  anti-mouse  IgG,  mouse 
peroxidase-conjugated  anti-peroxidase
 com-
plexes,  and  mouse  alkaline  phosphatase-
conjugated  anti-alkaline
  phosphatase 
complexes were purchased from Dakopatts 
(Glostrup,
 Denmark).
  
 
MIF  expression  using  Immunohistoche-
mistry Staining: 
         Two-color  immunohistochemistry 
staining  was  performed  as  described
 
previously  (Lan  et  al.,  2000).  Paraffin 
sections  (4  µm)  were  treated
 with  10-min 
microwave oven heating in 10 mM sodium 
citrate,
 pH 6.0, at 2450 MHz and 800 W. 
Sections  then  were  preincubated
 with  10% 
fetal  calf  serum  and  10%  normal  goat 
serum  in  PBS  for
  20  min,  drained,  and 
incubated  with  KP1  or  UCHL1  MoAb 
overnight
  at  4°C.  Sections  then  were 
washed  in  PBS,  endogenous  peroxidase
 
inactivated  in  0.3%  H2O2  in  methanol, 
incubated  with  peroxidase-conjugated
  goat 
anti-mouse IgG, washed in PBS, incubated 
with  mouse  peroxidase-conjugated
  anti-
peroxidase  complexes,  and  developed  with 
3,3-diaminobenzidine
  to  produce  a  brown 
colour.  Slides  then  underwent  a  second 
microwave
 treatment to denature the bound 
Ig  and  prevent  antibody  cross
  reactivity 
(Lan  et  al.,  1995).  Sections  then  were 
preincubated with 10% fetal
 calf serum and 
10% normal goat serum in PBS for 20 min, 
followed
 by 10%  bovine  serum  albumin  in 
PBS for 20 min, washed,  and labeled
 with 
the anti-MIF MoAb overnight at 4°C. After 
washing  in
  PBS,  sections  then  were 
incubated  sequentially  with  alkaline
 
phosphatase-conjugated  goat  anti-mouse 
IgG  and  mouse  alkaline
  phosphatase-
conjugated  anti-alkaline  phosphatase 
complexes  and
  then  developed  with  Fast 
Blue BB Salt (Ajax Chemicals, Melbourne,
 
Australia).  Sections  were  counterstained 
with  periodic  acid–Schiff
  (minus 
hematoxylin)  and  mounted  in  an  aqueous 
medium.
  
 
Quantitation  of  Immunohistochemistry 
Staining   
         The  number  of  immunostained  cells 
were counted under high-power
 microscope 
fields  (x400)  in  all  glomeruli  (10-30)  for 
each
 biopsy and  expressed  as cell  per  gcs. 
The  number  of  KP1-positive
 and  UCHL1-
positive  interstitial  cells  was  counted  in 
high-power
 fields of the cortex with a 0.02-
mm
2  graticule  fitted  in  the
 eyepiece  of  the 
microscope  for  the  entire  biopsy  and 
expressed
 as cells per square millimeter. No 
adjustment of the interstitial
 cell count was 
made  for  tubules  or  the  luminal  space. 
Cortical
 tubular  MIF  staining  was  scored 
from  the  entire  cortex  of  the
 biopsy  and Nahla Khattab et al     
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expressed  as  the  percentage  of  positive 
tubules.
 Data are expressed as means ± SD.  
Statistical Analysis 
         Results are expressed as mean  SD. 
Comparisons  were  made  by  student  t-test 
for  independent  groups  and  by  paired 
samples  t-test  for  dependent  groups. 
Correlations  between  variables  were  tested 
by Pearson correlation coefficient, p< 0.05 
was considered statistically significant. 
 
Results 
 
         Twenty  SLE  female  patients,  with 
mean age of 35.1510.42 years (range18-53 
years), mean disease duration of 3.68 2.45 
years (range 0.5- 10 years) were enrolled in 
this study. The results of lab works showed 
that 15 patients had positive ANA (75 %), 
17  patients  had  positive  anti-dsDNA  (85 
%).  The  mean  serum  creatinine  levels  of 
patients  was  1.8    1.69  mg/dl.  Patients 
showed a mean SLEDAI score of 5.552.54 
and a mean SLICC/ACR DI of 3.152.01. 
The  mean  steroid  dose  for  patients  was 
25.1319.59  mg/day.  Four  renal  biopsies 
taken  from  patients  showed  SLE  WHO 
class  IV,  two  biopsies  showed  class  III, 
while  one  showed  class  II.  Clinical  and 
laboratory data are shown in table 1. 
         Our  Biochemical  results  showed  that 
there  was  a  statistically  significant  2.98-
fold increase in mean urinary MIF (U MIF) 
levels in SLE patients (621.35 330.65 pg 
MIF/µmol,  range  148  to  1290)  than  in 
controls (208.5102.53, range 53 to 420 pg 
MIF/µmol)  P<  0.05.  While,  mean  serum 
MIF  (S  MIF)  showed  no  statistical 
significant  difference  between  cases 
(949.4693.48,  range  210  to  2005  pg/ml) 
and  control  (599.9460.08,  range  105  to 
1760 pg/ml) P>0.05 
         Also, there was a positive correlation 
between  disease  damage  index 
SLICC/ACR DI  and both  S MIF  (r=0.82, 
P<0.05)  (fig  1A),  and  U  MIF  (r=0.92, 
P<0.05) (fig 1B). However, disease activity 
(SLEIDAI)  scores  did  not  show  any 
correlation  with  either  S  MIF  (r=  -0.18 
P=0.44), or with U MIF (r= -0.25 P=0.29). 
                           A statistically significant higher mean 
level of serum creatinine was found in SLE 
patients  (1.81.69mg/dl)  compared  to 
control (0.50.23mg/dl) P< 0.05. There was 
also  a  positive  correlation  between  S  MIF 
and S creatinine P<0.05 (Fig 2)  
         Corticosteroid  doses  showed  a  mean 
of  25.13  ±  19.59  mg/day  in  SLE  patients 
and  showed  a  highly  positive  correlation 
with  both  S  MIF  (r=0.95,  P<0.0001)  and 
serum creatinine (r= 0.9, P<0.0001 (Fig 3). 
There was also a highly positive correlation 
between  steroid  dose  and  SLICC/ACR  DI 
(r=0.77, P<0.0001). 
                           O Ou ur r    h hi is st to op pa at th ho ol lo og gi ic c    r re es su ul lt ts s    o of f    t th he e    7 7   
r re en na al l    S SL LE E    s sp pe ec ci im me en ns s    i in nd di ic ca at te ed d    t th ha at t    f fo ou ur r   
r re en na al l   b bi io op ps si ie es s   s sh ho ow we ed d   S SL LE E   W WH HO O   c cl la as ss s   I IV V, ,   
t tw wo o    b bi io op ps si ie es s    s sh ho ow we ed d    c cl la as ss s    I II II I, ,    w wh hi il le e    o on ne e   
s sh ho ow we ed d    c cl la as ss s    I II I    g gl lo om me er ru ul lo on ne ep ph hr ri it ti is s    ( (G GN N) ). .   
N No ot t    o on nl ly y    d di id d    t th he e    m me ea an n    u ur ri in na ar ry y    M MI IF F    ( (U U   
M MI IF F) )    l le ev ve el ls s    i in n    S SL LE E    p pa at ti ie en nt ts s    s sh ho ow we ed d    a a   
s st ta at ti is st ti ic ca al ll ly y    s si ig gn ni if fi ic ca an nt t    2 2. .9 98 8- -f fo ol ld d    i in nc cr re ea as se e   
( (6 62 21 1. .3 35 5     3 33 30 0. .6 65 5    p pg g    M MI IF F/ /µ µm mo ol l) )    t th ha an n    i in n   
c co on nt tr ro ol ls s    ( (2 20 08 8. .5 5 1 10 02 2. .5 53 3p pg g    M MI IF F/ /µ µm mo ol l) ), ,    b bu ut t   
a al ls so o   a a   p po os si it ti iv ve e   c co or rr re el la at ti io on n   w wa as s   f fo ou un nd d   b be et tw we e- -
e en n    t th he e    d di if ff fe er re en nt t    g gr ra ad de es s    o of f    r re en na al l    a af ff fe ec ct ti io on n   
a an nd d   t th he e   U U   M MI IF F   ( (r r= =0 0. .8 82 2, ,   P P< <0 0. .0 05 5. .   f fi ig gu ur re e   4 4) ). .      
                           A Al ls so o, ,   t th hr re ee e   o of f   t th he e   7 7   b bi io op ps si ie es s   e ex xa am mi in ne ed d   
s sh ho ow we ed d    s se ev ve er re e    g gl lo om me er ru ul la ar r
    h hy yp pe er rc ce el ll lu ul la ar ri it ty y   
( (> >1 12 20 0    c ce el ll ls s/ /g gc cs s) ), ,    3 3    s sh ho ow we ed d    m mo od de er ra at te e   
h hy yp pe er rc ce el ll lu ul la ar ri it ty y    ( (9 90 0- -1 12 20 0    c ce el ll ls s/ /g gc cs s) ), ,    w wh hi il le e   
o on ne e    s sh ho ow we ed d    m mi il ld d    h hy yp pe er rc ce el ll lu ul la ar ri it ty y    ( (6 60 0- -9 90 0   
c ce el ll ls s/ /g gc cs s) ). .    T Th he e    d de et te ec ct te ed d    g gl lo om me er ru ul la ar r   
h hy yp pe er rc ce el ll lu ul la ar ri it ty y    h hi ig gh hl ly y    p po os si it ti iv ve el ly y    c co or rr re el la at te ed d   
w wi it th h   b bo ot th h   S S   M MI IF F   ( (r r= =0 0. .8 85 5, ,   P P= =0 0. .0 02 2; ;   F Fi ig g   5 5A A) )   
a an nd d   U U   M MI IF F   ( (r r= =0 0. .8 89 9, ,   P P= =0 0. .0 00 07 7; ;   F Fi ig g   5 5B B) ). .      
                           I Im mm mu un no oh hi is st to oc ch he em mi is st tr ry y    s st ta ai in ni in ng g    o of f    a al ll l   
n no or rm ma al l    k ki id dn ne ey y    s sp pe ec ci im me en ns s    s sh ho ow we ed d    t th ha at t    M MI IF F   
i is s    c co on ns st ti it tu ut ti iv ve el ly y    w we ea ak kl ly y    e ex xp pr re es ss se ed d    b by y    s so om me e   
g gl lo om me er ru ul la ar r    a an nd d    p pa ar ri ie et ta al l    e ep pi it th he el li ia al l    c ce el ll ls s    a an nd d   
b by y   m mo os st t   t tu ub bu ul la ar r   e ep pi it th he el li ia al l   c ce el ll ls s. .   I In n   c co on nt tr ra as st t, ,   
t th he er re e    w wa as s    a a    s si ig gn ni if fi ic ca an nt t    i in nc cr re ea as se e    i in n
   
g gl lo om me er ru ul la ar r   a an nd d   t tu ub bu ul la ar r   M MI IF F   p pr ro ot te ei in n   s st ta ai in ni in ng g   
i in n   S SL LE E   n ne ep ph hr ro op pa at th hy y   ( (F Fi ig g   6 6) ). .   T Th hi is s   i in nc cr re ea as se ed d   
M MI IF F    e ex xp pr re es ss si io on n    c co or rr re el la at te ed d    p po os si it ti iv ve el ly y    w wi it th h   
b bo ot th h   S S   M MI IF F   ( (r r= =0 0. .8 89 9, ,   P P= =0 0. .0 00 07 7) )   ( (F Fi ig g   7 7A A) ), ,   a an nd d   
U U    M MI IF F    ( (r r= =0 0. .8 82 2, ,    P P= =0 0. .0 02 2) )    ( (F Fi ig g    7 7B B) ). .    M MI IF F   
e ex xp pr re es ss si io on n    a al ls so o    c co or rr re el la at te ed d    p po os si it ti iv ve el ly y    w wi it th h   
S SL LI IC CC C/ /A AC CR R    D DI I    ( (r r= =0 0. .8 89 9, ,    P P= =0 0. .0 00 08 8) )    ( (F Fi ig g   
8 8A A) ), ,    a an nd d    t th he e    d da ai il ly y    s st te er ro oi id d    d do os se e    ( (r r= =0 0. .8 82 2, ,   
P P= =0 0. .0 02 2) )   ( (F Fi ig g   8 8B B) ), ,   b bu ut t   n no ot t   w wi it th h   S SL LE ED DA AI I   ( (r r= =   
- -0 0. .4 46 6, ,    P P= =0 0. .3 3) ). .    A Ag ga ai in n, ,    s st tu ud dy yi in ng g    t th he e   
c co or rr re el la at ti io on n   b be et tw we ee en n   t th he e   h hy yp pe er rc ce el ll lu ul la ar ri it ty y   a an nd d   
e ei it th he er r   t th he e    S SL LI IC CC C/ /A AC CR R    o or r   t th he e    s st te er ro oi id d    d do os se e, ,   M Ma ac cr ro op ph ha ag ge e   M Mi ig gr ra at ti io on n   I In nh hi ib bi it to or ry y   F Fa ac ct to or r   i in n   S Sy ys st te em mi ic c……… ………   
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w we e    f fo ou un nd d    a a    p po os si it ti iv ve e    c co or rr re el la at ti io on n    b be et tw we ee en n   
h hy yp pe er rc ce el ll lu ul la ar ri it ty y      a an nd d   b bo ot th h   v va ar ri ia ab bl le es s   ( (r r= =0 0. .9 95 5, ,   
0 0. .8 87 7; ;   P P= =0 0. .0 00 01 1   a an nd d   0 0. .0 01 1, ,   r re es sp pe ec ct ti iv ve el ly y) )   ( (F Fi ig g   9 9   
A A   a an nd d   B B) ). .   
     
 
 
Table (1): Showing the clinical and laboratory data of both groups  
 
 
  SLE cases (N=20)  Controls (N=10)  t  S 2-tail) 
  Mean  SD  Mean  SD 
Age   35.15  10.42  33.20  11.43  -.468  0.643 
Disease duration  3.68  2.45         
S creatinine  1.8  1.69  0.5  0.23  -2.405  0.023 
SLEDAI  5.55  2.54         
SLICC/ACR DI  3.15  2.01         
S MIF  949.4  693.48  599.9  460.08  -1.437  0.162 
U MIF  621.35  330.65  208.5  102.53  -3.827  0.001 
Steroid dose  25.13  19.59         
G hypercellularity  112.14  19.8         
GN grade   3.43  0.79         
MIF expression  2.43  0.79         
   
 
Figure (1): Correlation between disease damage index (SLICC/ACR DI) and both 
A)serum and B)urinary MIF 
 
 
A) disease damage index (SLICC/ACR DI) 
with S MIF 
B) disease damage index (SLICC/ACR DI) 
with U MIF 
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Figure (2): Showing the correlation between S MIF   and S creatinine 
 
S MIF                        r=0.86 P<0.0001
S creatinine
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Figure (3): Correlation between steroid dose and A) S MIF and B) serum creatinine 
 
   
A) steroid dose with S MIF  B) steroid dose with serum creatinine 
S MIF                      r=0.95 P<0.0001
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S creatinine                         r=0.90 P<0.0001
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Figure (4): Correlation between different grades of renal affection and U MIF 
 
U MIF                               r=0.82 P=0.02
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4 3 2
1300
1200
1100
1000
900
800
700
600
   
   
   
F Fi ig gu ur re e   ( (5 5) ): :   C Co or rr re el la at ti io on n   b be et tw we ee en n   g gl lo om me er ru ul la ar r   h hy yp pe er rc ce el ll lu ul la ar ri it ty y   i in n   r re en na al l   s sp pe ec ci im me en ns s   a an nd d   A A) )   S S   
M MI IF F   a an nd d   B B) )   U U   M MI IF F   
   
   
A A) )   G Gl lo om me er ru ul la ar r   h hy yp pe er rc ce el ll lu ul la ar ri it ty y   w wi it th h   S S   M MI IF F    B B) )   G Gl lo om me er ru ul la ar r   h hy yp pe er rc ce el ll lu ul la ar ri it ty y   w wi it th h   U U   M MI IF F   
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F Fi ig gu ur re e    ( (6 6) ): :    D Do ou ub bl le e    i im mm mu un no oh hi is st to oc ch he em mi is st tr ry y    s st ta ai in ni in ng g    o of f    M MI IF F    ( (b bl lu ue e) )    a an nd d    l le eu uk ko oc cy yt ti ic c   
i in nf fi il lt tr ra at ti io on n    ( (b br ro ow wn n) )    i in n    S SL LE E    n ne ep ph hr ri it ti is s    s sh ho ow wi in ng g    m ma ar rk ke ed d    c co on ns st ti it tu ut ti iv ve e    M MI IF F    e ex xp pr re es ss si io on n    b by y   
s so om me e    g gl lo om me er ru ul la ar r    c ce el ll ls s    a an nd d    a ap pp pr ro ox xi im ma at te el ly y    h ha al lf f    o of f    t th he e    c co or rt ti ic ca al l    t tu ub bu ul le es s    i in n    a as ss so oc ci ia at ti io on n    w wi it th h   
p pr ro om mi in ne en nt t   f fo oc ca al l   a ac cc cu um mu ul la at ti io on n   o of f   m ma ac cr ro op ph ha ag ge es s. .      
   
   
                                        
      
   
   
F Fi ig gu ur re e   ( (7 7) ): :   C Co or rr re el la at ti io on n   b be et tw we ee en n   M MI IF F   e ex xp pr re es ss si io on n   i in n   r re en na al l   s sp pe ec ci im me en ns s   a an nd d   A A) )   S S   M MI IF F   a an nd d   B B) )   
U U   M MI IF F   
   
A A) )   M MI IF F   e ex xp pr re es ss si io on n   w wi it th h   S S   M MI IF F    B B) )   M MI IF F   e ex xp pr re es ss si io on n   w wi it th h   U U   M MI IF F   
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F Fi ig gu ur re e   ( (8 8) ): :   C Co or rr re el la at ti io on n   b be et tw we ee en n   M MI IF F   e ex xp pr re es ss si io on n   i in n   r re en na al l   s sp pe ec ci im me en ns s   a an nd d   A A) )   S SL LI IC CC C/ /A AC CR R   
D DI I   a an nd d   B B) )   s st te er ro oi id d   d do os se e   
   
A A) )   M MI IF F   e ex xp pr re es ss si io on n   w wi it th h   S SL LI IC CC C/ /A AC CR R   D DI I    B B) )   M MI IF F   e ex xp pr re es ss si io on n   w wi it th h   s st te er ro oi id d   d do os se e   
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F Fi ig gu ur re e   ( (9 9) ): :   C Co or rr re el la at ti io on n   b be et tw we ee en n   g gl lo om me er ru ul la ar r   h hy yp pe er rc ce el ll lu ul la ar ri it ty y   i in n   r re en na al l   s sp pe ec ci im me en ns s   a an nd d   A A) )   
S SL LI IC CC C/ /A AC CR R   D DI I   a an nd d   B B) )   s st te er ro oi id d   d do os se e   
   
A A) )    G Gl lo om me er ru ul la ar r    h hy yp pe er rc ce el ll lu ul la ar ri it ty y    w wi it th h   
S SL LI IC CC C/ /A AC CR R   D DI I   
B B) )    G Gl lo om me er ru ul la ar r    h hy yp pe er rc ce el ll lu ul la ar ri it ty y    w wi it th h    s st te er ro oi id d   
d do os se e   
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Discussion 
    
         Although the etiology of SLE remains 
unknown, it is clear that patients with SLE 
have  a  wide  variety  of  immunoregulatory 
abnormalities  leading  to  autoimmune 
mediated organ injury. Immmunoregulatory 
abnormalities  observed  in  SLE  include 
hyperresponsive  B  cells  and  abnormal 
antibody production, as well as abnormal T 
cell  responses  (Lipsky,  2001).  MIF  has 
been  identified  as  a  mediator  of  activation 
of B and T cells (Chesney et al., 1999), as 
well as of synovial cells, endothelium, and 
glomerular cells  (Sampey  et  al.,  2001).  In 
addition, MIF is expressed in inflammatory 
lesions in organs targeted by SLE including 
joints, kidney, bowel, skin, and brain. It is 
increasingly  accepted  that  MIF  contributes 
to the pathogenesis of autoimmune  inflam-Nahla Khattab et al     
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matory  diseases  including  RA,  immune 
glomerulonephritis,  inflammatory  bowel 
disease,  psoriasis,  and  multiple  sclerosis 
(Leech et al., 2000). 
         The  range  of  effects  of  MIF  in  the 
immune system, and its expression in target 
organs of SLE, led us to the hypothesis that 
MIF  is  involved  in  the  pathogenesis  of 
inflammatory  organ  injury  in  SLE.  Our 
results  show  that  patients  with  SLE  were 
more  likely  to  have  elevated  serum  MIF 
concentrations  than  controls.  This  contr-
adicts  the  report  done  by  Mizue  et  al 
(2000),  in  which  a
  fourfold  increase  in 
serum MIF levels was described in patients
 
with  SLE.  Unfortunately,  this  report  gave 
no  patient  details,
 so  that  the  severity  and 
systemic symptoms in these SLE  cases
 are 
unknown,  thus  making  it  difficult  to 
compare  with  the  patient
  group  in  this 
study.  One  possible  explanation  for  the 
apparent
  discrepancy  is  that  increased 
serum  MIF  reflects  systemic  symptoms
 
because the SLE patient group in this study 
had  primarily  renal
  involvement  without 
systemic disease. Further studies are needed
 
to clarify this issue.
  
         Disease related damage, as measured 
using  the  SLICC/ACR  DI  was  greater  in   
patients  with  higher  serum  MIF  concent-
ration. This association was independent of 
current  corticosteroid  dose.  Similarly, 
patients  with  high  SLICC/ACR  DI  scores 
were  more  likely  to  have  abnormally 
elevated values  of  serum  MIF.  These  data 
suggest that serum MIF is associated  with 
disease  severity  in  SLE.  Possible 
explanations of this could include MIF gene 
polymorphisms,  such  as  those  recently 
described  in  patients  with  inflammatory 
arthritis (Baugh et al., 2002). 
         We were unable to find a relationship 
between  serum  MIF  and  disease  activity 
score,  as  our  study  included  patients  with 
very low disease activity scores. 
         Our  analysis  of  the  relationship 
between serum MIF and corticosteroid  use 
in SLE  patients  showed  that  corticosteroid 
use  was  positively  associated  with  serum 
MIF,  particularly  at  higher  doses,  which 
confirms the results reported by Foote et al 
(2004). 
         This  study  demonstrates  that  MIF  is 
readily  detected  in  the
  urine  of  normal, 
healthy volunteers.  Urinary  MIF  was  incr-
eased
 about 2.98 fold over normal levels in 
the  SLE  patients.  The  urine  MIF  concen-
tration  correlated  with  the
 degree  of  renal 
dysfunction,  histologic  damage,  leukocytic 
infiltration,
 and renal MIF expression. 
         The  increase  in  urinary  MIF 
concentration  seen  in  SLE  patients  is 
probably  the  result  of  increased  local 
production
 and secretion of MIF within the 
injured  kidney.  This  postulate
 is  supported 
by  two  findings.  There  was  a  significant
 
correlation  between  renal  MIF  expression 
assessed  by  immunohistochemistry
 staining 
and  the  urine  MIF  concentration.  MIF 
expression was
 increased in the glomerulus 
(resident and infiltrating mononuclear
 cells) 
and in tubular epithelial cells, both potential
 
sites  of  MIF  secretion  into  the  urinary 
space. In support of
 this concept, Rice et al. 
(1999)  have  reported  that  interferon 
gamma, a cytokine implicated in the devel-
opment of kidney disease, can induce
 rapid 
secretion  of  MIF  by  mesangial  cells  and 
tubular  epithelial
  cells  in  vitro  and 
suggested  in  a  recent  study  done  in  2003 
that  this  may  be  an  important  mechanism 
leading  to  inflammatory  cell  accumulation 
and  activation  during  kidney  disease.  The 
increase  in  MIF  immunostaining  in  the 
biopsy
  tissues  is  consistent  with  the 
previous
 study done by Lan et al. (2000) in 
which the upregulation of MIF mRNA and 
protein  expression
  was  described  in  a 
different cohort of GN patients.  
         This  study  has  shown  that  in  an 
individual patient, the  urine
 and renal  MIF 
correlated with the severity and activity  of 
GN
  (glomerular  hypercellularity  and 
crescent formation, the degree
 of interstitial 
damage,  mononuclear  cell  infiltrate,  and 
loss
 of renal function). Therefore, the urine 
MIF  concentration  may
  be  useful  in 
monitoring  patients  for  the  degree  of 
disease  activity.
  However,  Brown  et  al. 
(2002) found that urine MIF concentration 
is not useful in identifying
 a specific type of 
GN in an individual patient, although a high
 
urine MIF level does suggest a more severe 
proliferative   form
  of  GN. Further studies 
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 are  needed  to  assess  how  urine  MIF 
excretion
 changes  with  time  in  individual 
patients.  In  particular,  it
  is  important  to 
determine  whether  urine  MIF  could  be  an 
early
 indicator of a flare of disease activity.
  
         In summary, this study found that the 
serum concentration of MIF is more likely 
to  be  elevated  above  the  normal  range  in 
SLE,  as  in  other  inflammatory  diseases. 
Also,  urine  MIF  concentration
 is  signific-
antly  increased  in  SLE  World  Health 
Organization  class  IV  and
 correlated  with 
the degree of renal dysfunction, histological
 
damage,  and  leukocytic  infiltration. 
Prospective  studies  of  the  association 
between  MIF  and  disease  activity  using 
validated  indices  of  disease  activity,  and 
including  patients  with  active  disease,  are 
required. 
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ءازمحنا ةبئذنا ضزم ىف جافوزكمنا لاقتولإ طبثمنا مماعمن  
ىهكنا باهتناب ةبىحصمنا تلااحنا ىف اههيثمتو  
 
باطخ ةههو
1  , راشىنا داهو
1  , ردب هيفيو
2  , ىمهف ناىح
2  , ىمهف ايخار
2  ,  ةههو
ضىع
2  
1 - عاؼشلإا ايجٕنُٕكذ ٔ زٕذثن ٗيٕقنا شكزًنا 2 -   ةطنا حيهك  ,  ضًش ٍيػ حؼياج - جزْاقنا -
زصي  
 
 
ثحبنا فادهأ  
  ال ٔزكاًنا لالقرَلإ ظثلبًنا ملياؼًنا ًٍضذ لاًردا ٗنا مصٕرنا  ٗنا حطاردنا جذْ ٍي فدٓذ
 ظثلبًنا ملياؼًنا ٖٕرظي صايق اضيأ ٌٔشيذرٕكنا حػزجت ّرقلاػٔ ءازًذنا حثئذنا ضزي ٗ 
ءازلًذنا حلثئذنا ضزلي لٕلتٔ ملصي ٗل   ال ٔزكاًنا لاقرَلإ  .  دليدذذ  حلطاردنا د دٓرلطا الًك
ميبًذ   ٗهكنا بآرنات حتٕذصًنا خلااذنا ٗ  ٖٕهكنا  ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا .  
 
ثحبنا قزط  
 حليًيشَلإا حلقيزطنات لٕلثنأ ملصًنا ٗل   ال ٔزكاًنا لالقرَلإ ظثلبًنا ملياؼًنا شليكزذ صايق ىذ
 ٍي ضزًهن ةداصي ٖٕهك بآرنات حتٕذصًنأ ءازًذنا حثئذنا خاضيزي زشػ ٗ  حيػاًُنا
نا حجردنا  خاديلظنا  جزلشػ ٗل ٔ حليًناؼنا حذصنا حًظُي خاجرد ةظد حؼتازنأ حبنابنا ،حيَاب
ٖزللًؼنا ظللطٕرًنا ضلللَ ٍللي ءاذللصلأا  .  ٗللكيُيهك   للذ  ٗللنا خاللضيزًنا مللك دؼللضع دللقٔ
حيهًؼي ميناذذٔ مصلي  .  ٍلػ ٖٕلهكنا  ال ٔزكاًنا لالقرَلإ ظثلبًنا ملياؼًنا مليبًذ ىيليقذ ىذ دقٔ
لأا خاُيؼن حيػاًُنا حغثصنا قيزط حجظَ .  
 
حئاتو   ثحبنا  
 ملصًنا ٗل   ال ٔزكاًنا لالقرَلإ ظثلبًنا ملياؼًنا شليكزذ ٍيلت ةلجٕي طالثذرا ائالرُنا خزلٓظأ
 خا  خالضيزًنا ٗل  زلبكأ ضزلًهن فلهرنا خازلشري دلَاك دلق  ،ءازًذنا حثئذنا ضزي فهذٔ
ملصًنا ٗل  ٗلؼيثطنا ظلطٕرًنا لدلؼًنا ٍلي ٗلهػأ  ال ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا شيكزذ  .
ًك  حيئاصد  حنلادت ٗهػأ ٌاك مصًنا ٗ   ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا شيكزذ ٌأ عدٕن ا
 فهذ مياؼي حجرد خا  خاضيزًنا ٗ  ≤   3 .  
 حػزجت اثجٕي اطاثذرا ظثذزي ٌاك مصًنا ٗ   ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا ٌأ دجٔ اًك
حيدمرلظًنا ٌٔشيذرٕلكنا  . لقرَلإ ظثلبًنا ملياؼًنا ٌأ دلجٔ الًك  ٌاللك ملصًنا ٗل   ال ٔزكاًنا لا
 ٔا ضزًنا فهذ ٗهػ دًرؼي زيغ مكشت مصًنا ٗ  ٍيُذايزكنا شيكزذ غي ايثهط اطاثذرا ظثذزي
ٌٔشيذرٕكنا حػزج .  
 ٗلهػأ ٌالك لٕلثنا ٗ   ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا شيكزذ ٌأ اضيا ائارُنا دذضٔأ اًك
 لدؼًت 2..2    ٗل  ّلُػ ءازلًذنا حلثئذنا خالضيزي ٗل  جزلي ءاذلصلأا  .  حغثلصنا دذلضٔأ الًك
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 ملليبًرنا اذللْ ٌاللكٔ ٗللهكنا باللٓرنات حتٕذللصًنأ ءازللًذنا حللثئذنا خاللضيزي ٗلل   الل ٔزكاًنا
 ايلاعٔ  ا ٔزكًهن حاشذرإت بٕذصي ( خ .)  
يت حيئاصد  حنلاد ٔ  طاثذرا دجٔ اًك  لٕلثنا ٗل   ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا ٖٕرظي ٍ
 ظثلبًنا ملياؼًنا ردلصي ٌأ خلضٕي الًي ملصًنا ٗل  ِإرلظي غلي ضين ٍكنٔ ٗهكنا ٗ  ّهيبًذٔ
ٗهكنا ْٕ لٕثنا ٗ   ا ٔزكاًنا لاقرَلإ  .  
 فلهرنا ،ٗلهكنا زرثلذ حجرد غي لٕثنا ٗ   ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا ٖٕرظي ظثذرا اًك
ظٓنا لٕثنا ٗ  ٍيذٔزثنا حيًك غي ضين ٍكنٔ ءاضيثنا ودنا ايلاع حاشذر ٔ ٗجٕنٕر   .  
 
جاتىتسلإا  
 ضزي ٗ  ٗهػأ مصًنا ٗ   ا ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا ٖٕرظي ٌأ حطاردنا ٍي اُرظي
 حلثئذنا ٗلضزي ٗل  ايئالصد  ٗلهػأ لٕثنا ٗ  ِإرظي ٌأ اًك ءاذصلأا ٗ  ُّػ ءازًذنا حثئذنا
 ٍي ءازًذنا  حلجرد غلي ِإرلظي ةلطاُرئ حيًناؼنا حذصنا حًظُي خاجرد ٍي حؼتازنا حجردنا
ٗهكنا حتاص   .  حلجرد لٕلثنا ٗل   ال ٔزكاًنا لاقرَلإ ظثبًنا مياؼًنا ٖٕرظي ضكؼي كن  ٗهػٔ
ٗهكنا ٗ  مياؼًنا ميبًذ         .  
 
 
     
 
   